Zacks Investment Research cut shares of Inotiv (NASDAQ:NOTV) from a buy rating to a sell rating in a report issued on Wednesday morning, Zacks.com reports. According to Zacks, “Inotiv Inc. is a pharmaceutical development company. It involved in providing contract research services and monitoring instruments to emerging pharmaceutical companies. Inotiv Inc., formerly known as Bioanalytical […]
Inotiv is a leading mid-market CRO offering a full suite of non-clinical services. NOTV has been on an acquisition spree, latest being Envigo, upping its game to full programs. Read more.
Hagens Berman urges XL Fleet Corp. (NYSE: XL) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims.
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Feb. 16) 10X ...